Absolute Risk Reduction of Shingrix for Preventing Shingles

Efficacy Data from Pivotal Trials

• The Centers for Disease Control and Prevention recommends Shingrix for adults aged 50 years and older, with a vaccine efficacy of 97.2% across all age groups 50 years and older 1

Durability of Protection

• Protection with Shingrix remains robust with efficacy maintained above 83.3% for at least 8 years post-vaccination 1, 2
• At 10 years, efficacy decreases to approximately 73% 1

Comparison to Previous Vaccine

• The American Academy of Family Physicians notes that Shingrix provides substantially greater absolute benefit than the older Zostavax vaccine, with Zostavax having a vaccine efficacy of only 51.3% in preventing herpes zoster in adults aged 60+ years 1
• Zostavax efficacy declines dramatically with age: 70% (ages 50-59) down to only 18% (ages 80+) 1, 2
• By year 10, Zostavax efficacy drops to only 14.1% 2